Mesenchymal stem cells and cardiac repair

J Cell Mol Med. 2008 Oct;12(5B):1795-810. doi: 10.1111/j.1582-4934.2008.00457.x. Epub 2008 Aug 5.

Abstract

Accumulating clinical and experimental evidence indicates that mesenchymal stem cells (MSCs) are promising cell types in the treatment of cardiac dysfunction. They may trigger production of reparative growth factors, replace damaged cells and create an environment that favours endogenous cardiac repair. However, identifying mechanisms which regulate the role of MSCs in cardiac repair is still at work. To achieve the maximal clinical benefits, ex vivo manipulation can further enhance MSC therapeutic potential. This review focuses on the mechanism of MSCs in cardiac repair, with emphasis on ex vivo manipulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone Morphogenetic Proteins / genetics
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Extracellular Matrix / physiology
  • Genetic Engineering
  • Heart Diseases / therapy*
  • Humans
  • Intercellular Signaling Peptides and Proteins / pharmacology
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / physiology*
  • Myocardium / cytology*
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / physiology*
  • Neovascularization, Physiologic

Substances

  • Bone Morphogenetic Proteins
  • Intercellular Signaling Peptides and Proteins